Market closedNon-fractional
Adicet Bio/ACET
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Adicet Bio
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Ticker
ACET
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
143
Website
www.adicetbio.com
Adicet Bio Metrics
BasicAdvanced
$124M
Market cap
-
P/E ratio
-$2.68
EPS
1.76
Beta
-
Dividend rate
Price and volume
Market cap
$124M
Beta
1.76
Financial strength
Current ratio
14.338
Quick ratio
14.18
Long term debt to equity
6.458
Total debt to equity
7.742
Interest coverage (TTM)
-16,265.63%
Management effectiveness
Return on assets (TTM)
-27.20%
Return on equity (TTM)
-53.25%
Valuation
Price to book
0.48
Price to tangible book (TTM)
0.48
Price to free cash flow (TTM)
-0.825
Growth
Earnings per share change (TTM)
6.74%
3-year earnings per share growth (CAGR)
-12.65%
What the Analysts think about Adicet Bio
Analyst Ratings
Majority rating from 9 analysts.
Adicet Bio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$28M
-4.76%
Profit margin
0.00%
NaN%
Adicet Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.75
-$1.16
-$0.69
-$0.35
-
Expected
-$0.68
-$0.74
-$0.69
-$0.39
-$0.37
Surprise
10.04%
57.33%
-0.65%
-9.75%
-
Adicet Bio News
AllArticlesVideos
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
Business Wire·1 month ago
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Adicet Bio stock?
Adicet Bio (ACET) has a market cap of $124M as of July 26, 2024.
What is the P/E ratio for Adicet Bio stock?
The price to earnings (P/E) ratio for Adicet Bio (ACET) stock is 0 as of July 26, 2024.
Does Adicet Bio stock pay dividends?
No, Adicet Bio (ACET) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Adicet Bio dividend payment date?
Adicet Bio (ACET) stock does not pay dividends to its shareholders.
What is the beta indicator for Adicet Bio?
Adicet Bio (ACET) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Adicet Bio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.